FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002588081> ?p ?o ?g. }

• W3002588081 endingPage "2380" @default.
• W3002588081 startingPage "2365" @default.
• W3002588081 abstract "Background and Purpose Breast cancer is the leading cause of death in women worldwide, with resistance to current therapeutic strategies, including tamoxifen, causing major clinical challenges and leading to more aggressive and metastatic disease. To address this, novel strategies that can inhibit the mechanisms responsible for tamoxifen resistance need to be assessed. Experimental Approach We examined the effect of the novel, clinically-trialled, thiosemicarbazone anti-cancer agent, DpC, and its potential as a combination therapy with the clinically used estrogen receptor (ER) antagonist, tamoxifen, using both tamoxifen-resistant and -sensitive, human breast cancer cells (MDA-MB-453, MDA-MB-231 and MCF-7) in 2D and 3D cell-culture. Synergy was assessed using the Chou-Talalay method. The molecular and anti-proliferative effects of these agents and their combination was examined via Western blot, immunofluorescence and colony formation assays. Key Results Combinations of tamoxifen with DpC were highly synergistic, leading to potent inhibition of cell proliferation, colony formation, and ER-α transcriptional activity. The combination also more efficiently reduced major molecular drivers of proliferation of tamoxifen-resistant cells, including c-Myc, cyclin D1, and p-AKT, while up-regulating the cell cycle inhibitor, p27, and inhibiting oncogenic phosphorylation of ER-α at Ser167. Assessing these effects using 3D cell culture further confirmed the greater effects of DpC combined with tamoxifen in reducing ER-α expression, and that of the proliferation marker, Ki-67, in both tamoxifen-sensitive and -resistant MCF-7 spheroids. Conclusions and Implications These studies demonstrate that the synergistic combination of DpC with tamoxifen could be a promising new therapeutic strategy to overcome tamoxifen resistance in ER-positive breast cancer." @default.
• W3002588081 created "2020-01-30" @default.
• W3002588081 creator A5010643006 @default.
• W3002588081 creator A5015216800 @default.
• W3002588081 creator A5016902217 @default.
• W3002588081 creator A5017905338 @default.
• W3002588081 creator A5029756043 @default.
• W3002588081 creator A5044383349 @default.
• W3002588081 creator A5057781258 @default.
• W3002588081 date "2020-02-12" @default.
• W3002588081 modified "2023-10-15" @default.
• W3002588081 title "Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent,<scp>DpC</scp>" @default.
• W3002588081 cites W1502461041 @default.
• W3002588081 cites W1810933484 @default.
• W3002588081 cites W1813571362 @default.
• W3002588081 cites W1962607015 @default.
• W3002588081 cites W1966320080 @default.
• W3002588081 cites W1979700784 @default.
• W3002588081 cites W1989328822 @default.
• W3002588081 cites W1994930469 @default.
• W3002588081 cites W1997006452 @default.
• W3002588081 cites W2002526053 @default.
• W3002588081 cites W2004454023 @default.
• W3002588081 cites W2004867710 @default.
• W3002588081 cites W2005604825 @default.
• W3002588081 cites W2013074747 @default.
• W3002588081 cites W2015978691 @default.
• W3002588081 cites W2017350478 @default.
• W3002588081 cites W2019473688 @default.
• W3002588081 cites W2025005089 @default.
• W3002588081 cites W2031056915 @default.
• W3002588081 cites W2040547831 @default.
• W3002588081 cites W2043065181 @default.
• W3002588081 cites W2046405795 @default.
• W3002588081 cites W2047863929 @default.
• W3002588081 cites W2048228826 @default.
• W3002588081 cites W2050831491 @default.
• W3002588081 cites W2059454194 @default.
• W3002588081 cites W2061551473 @default.
• W3002588081 cites W2071306241 @default.
• W3002588081 cites W2072787342 @default.
• W3002588081 cites W2083771536 @default.
• W3002588081 cites W2084202366 @default.
• W3002588081 cites W2086407765 @default.
• W3002588081 cites W2089595068 @default.
• W3002588081 cites W2091849811 @default.
• W3002588081 cites W2096439168 @default.
• W3002588081 cites W2103562758 @default.
• W3002588081 cites W2105214585 @default.
• W3002588081 cites W2109388713 @default.
• W3002588081 cites W2112444654 @default.
• W3002588081 cites W2123697148 @default.
• W3002588081 cites W2128605357 @default.
• W3002588081 cites W2130998029 @default.
• W3002588081 cites W2137935883 @default.
• W3002588081 cites W2138364046 @default.
• W3002588081 cites W2143407490 @default.
• W3002588081 cites W2145359087 @default.
• W3002588081 cites W2147220774 @default.
• W3002588081 cites W2150081723 @default.
• W3002588081 cites W2175093120 @default.
• W3002588081 cites W2296031005 @default.
• W3002588081 cites W2321112275 @default.
• W3002588081 cites W2331628193 @default.
• W3002588081 cites W2478846246 @default.
• W3002588081 cites W2526916147 @default.
• W3002588081 cites W2592633594 @default.
• W3002588081 cites W2769830263 @default.
• W3002588081 cites W2771328536 @default.
• W3002588081 cites W2791419854 @default.
• W3002588081 cites W2793908840 @default.
• W3002588081 cites W2985843002 @default.
• W3002588081 cites W2987510459 @default.
• W3002588081 cites W2987819628 @default.
• W3002588081 doi "https://doi.org/10.1111/bph.14985" @default.
• W3002588081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7174880" @default.
• W3002588081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31975484" @default.
• W3002588081 hasPublicationYear "2020" @default.
• W3002588081 type Work @default.
• W3002588081 sameAs 3002588081 @default.
• W3002588081 citedByCount "14" @default.
• W3002588081 countsByYear W30025880812020 @default.
• W3002588081 countsByYear W30025880812021 @default.
• W3002588081 countsByYear W30025880812022 @default.
• W3002588081 countsByYear W30025880812023 @default.
• W3002588081 crossrefType "journal-article" @default.
• W3002588081 hasAuthorship W3002588081A5010643006 @default.
• W3002588081 hasAuthorship W3002588081A5015216800 @default.
• W3002588081 hasAuthorship W3002588081A5016902217 @default.
• W3002588081 hasAuthorship W3002588081A5017905338 @default.
• W3002588081 hasAuthorship W3002588081A5029756043 @default.
• W3002588081 hasAuthorship W3002588081A5044383349 @default.
• W3002588081 hasAuthorship W3002588081A5057781258 @default.
• W3002588081 hasBestOaLocation W30025880811 @default.
• W3002588081 hasConcept C121608353 @default.
• W3002588081 hasConcept C126322002 @default.
• W3002588081 hasConcept C199835354 @default.
• W3002588081 hasConcept C2776067312 @default.

• next